Letters to the Editor

Additional Comments on Screening Mammography



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2001 Sep 15;64(6):922-927.

to the editor: I appreciate the attention American Family Physician has placed on preventive medicine and Healthy People 2010.1 The article and editorial titled “Breast Cancer Diagnosis and Screening” and “Screening for Breast Cancer,” by Drs. Apantaku2 and Garr,3 respectively, address important issues. However, for the sake of completeness, both authors should have addressed the controversy over screening mammography in greater detail.

In 1997, the NIH panel recommendation4 process became politicized and ended with the recommendation that the patient “should decide for herself” (if patient is 40 to 49 years of age), because there was no proof of benefit. Lancet published a meta-analysis performed by the Nordic Cochrane Center.5 The meta-analysis was conducted to see why there had not been the observed decrease in breast cancer mortality expected from the 1993 meta-analysis.6 The Nordic Cochrane Center found a number of serious methodologic issues with the allocation process and the reporting of results from the trials from the 1993 meta-analysis. If only the higher quality trials are used, then there appears to be no benefit from screening mammography and, indeed, it may be harmful. This was observed across all age groups.

Screening mammography is a highly charged issue and should not be refuted or dismissed on the basis of one meta-analysis. However, those interested in women's health must consider the data and determine how to proceed with guidelines for mammography. I fear that we may find mammography to be as ineffective for screening as the once-promising autologous bone marrow transplant was for treating metastatic breast cancer. As family physicians, I believe we owe the women we care for very careful consideration of this difficult issue.

REFERENCES

1. United States Department of Health and Human Services, Public Health Service. Healthy people 2010. Conf ed. Washington, D.C.: 2000.

2. Apantaku L. Breast cancer diagnosis and screening. Am Fam Physician. 2000;62:596–602,605–6.

3. Garr D. Screening for breast cancer. Am Fam Physician. 2000;62:500–1.

4. NIH Consensus Statement. Breast cancer screening for women ages 40–49. 1997;15:1–35.

5. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000;355:129–34.

6. Nystrom L, Rutqvist LE, Walls S, Lindgren A, Lindquist M, Ryden S, et al. Breast cancer screening with mammography. Lancet. 1993;341:973–8.

to the editor: I read with great interest Dr. Apantaku's excellent review of breast cancer diagnosis.1 I thought that the description of the various screening techniques was especially useful, but I do have a question regarding the clinical breast examination as described in the article.

It is suggested in the review to gently squeeze the nipple for discharge during the routine examination, and this technique has been advocated previously.2 However, nipple discharge on palpation is found in many patients without breast pathology and has not been shown to be a prognostic factor in breast cancer.3 In one retrospective study, a group of 205 patients with evoked nipple discharge but without spontaneous discharge or mass had no evidence of carcinoma. The authors recommend routine follow-up for these patients.4

Does attempting to express nipple discharge further the inquiry into possible breast cancer? And would this finding without a history of spontaneous discharge or breast mass lead to any change in the routine screening protocol?

REFERENCES

1. Apantaku L. Breast cancer diagnosis and screening. Am Fam Physician. 2000;62:596–602.

2. Wyngaarden JB, Smith LH, Bennett JC. Cecil textbook of medicine. 19th ed. Philadelphia: Saunders, 1992:1380.

3. Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999;282:1270–80.

4. Gulay H, Bora S, Kilicturgay S, Hamaloglu E, Goskel HA. Management of nipple discharge. J Am Coll Surg. 1994;178:471–4.

in reply: Dr. Vega, differences of opinion do exist on whether or not nipple discharge should be elicited during an examination if there is no history of spontaneous discharge. The most important issue is whether or not the patient's history is taken regarding possible discharge.

Small amounts of spontaneous nipple discharge may not be apparent to the patient. The finding of elicited (nonspontaneous) discharge would lead to a discussion with the patient of what signs to look for that might represent suspicious discharge. One might consider a cytologic smear and close follow-up for elicited, unilateral bloody discharge in a woman older than 50 years, although, admittedly, the yield would be low.

It is certainly true that the signs of a suspicious discharge are spontaneous, bloody discharge from a single duct often associated with a mass.1 Although nipple discharge is usually insignificant, it is worrisome to the patient. Physicians can help relieve patients' anxiety by explaining the nature and origin of the discharge.

Dr. Sontheimer is correct that the entire article, if re-titled, could have discussed the controversy of whether or not women in their 40s should undergo screening mammograms. Because I could not definitively answer the question, I chose to include what I consider to be four balanced references on the subject and present other information regarding breast health.

The study by Gotzsche2 produced multiple correspondence3 that adds to the ongoing debate over this topic. The reference2 to screening mammography being potentially harmful refers primarily to the harm of having to go through a surgical procedure. Currently, most of these are done stereotactically with little morbidity and must be balanced against the possible benefit of survival. To compare screening mammograms with high-dose chemotherapy that resulted in a 10 percent mortality of the women undergoing the treatment is, I believe, unfair.

Breast cancer is an enormous issue in the mind of many women. With one in eight women diagnosed with breast cancer, most women have personal knowledge of a friend or relative with breast cancer. A majority of women with a family history of breast cancer have exaggerated perceptions of their risk and experience excessive anxiety.4 I believe that many women without family history have some anxiety. My own calculated risk for developing breast cancer in the next five years by the Gail model5 is 1.1. This is well below the 1.7 level recommended for consideration for chemoprevention. Even so, I have an annual sense of relief looking at my mammogram and seeing no signs of cancer.

It is important for us to educate our patients about the risks and benefits of all the procedures undertaken. It may be more expedient to tell a 40-year-old woman asking for a screening mammogram that the benefits have not been proved, than to have a discussion with every patient older than 40 years about the known risks (i.e., possible biopsy for a benign mass) versus possible benefits (i.e., finding a cancer at an earlier stage with a better prognosis for survival). Because I believe that at the present time the possible advantages outweigh the possible risks, I recommend annual screening mammograms for all women older than 40 years.

REFERENCES

1. Leis HP Jr. Management of nipple discharge. World J Surg. 1989;13:736–42.

2. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000;355:129–34.

3. Duffy SW. Tabar L Screening mammography reevaluated [Editorial]. Lancet. 2000;355:747–8.

4. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, et al. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst. 1995;87:286–92.

5. Breast Cancer Risk Assessment Tool for Health Care Providers. Office of Cancer Communication, National Cancer Institute, Bethesda, Maryland. Retrieved April 2001 from: http://bcra.nci.nih.gov/brc.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.



Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article